Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03598244 · ClinicalTrials.gov registry record · Phase 1
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
A Phase 1 study of Recurrent Malignant Glioma and Recurrent Medulloblastoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 12
- Study locations
NCT03598244 is a Phase 1 study of Recurrent Malignant Glioma and Recurrent Medulloblastoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 41 participants, above the 24-participant average among 17 other Recurrent Malignant Glioma trials with a reported enrollment target (71% higher). The trial reports 12 study locations across 10 states.
The verdict
NCT03598244, a Phase 1 study of Recurrent Malignant Glioma and Recurrent Medulloblastoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 12
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of volitinib in treating patients with primary central nervous system (CNS) tumors that have come back (recurrent) or does not respond to treatment (refractory). Volitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE X-Ray Imaging
- DRUG Savolitinib
Study Locations (12)
California
- Children's Hospital Los Angeles - Los Angeles
- Lucile Packard Children's Hospital Stanford University - Palo Alto
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- Lurie Children's Hospital-Chicago - Chicago
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Tennessee
- Saint Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2026-04-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03598244
The ClinicalTrials.gov registry entry for NCT03598244 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 24-participant average among 17 other Recurrent Malignant Glioma trials with a reported enrollment target (71% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Recurrent Malignant Glioma appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT03598244 reports 12 study locations spanning 10 distinct geographic areas - top geographies include California, Ohio, Colorado.
Frequently Asked Questions
What is clinical trial NCT03598244 about?
NCT03598244 is a clinical study titled "Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors". This phase I trial studies the side effects and best dose of volitinib in treating patients with primary central nervous system (CNS) tumors that have come back (recurrent) or does not respond to treatment (refractory). Volitinib may stop the growth of tumor cells by blocking some of the enzymes nee...
What is the current status of trial NCT03598244?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2018-11-27. Estimated completion is 2026-04-14.
What conditions does trial NCT03598244 study?
This clinical trial studies the following conditions: Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Diffuse Intrinsic Pontine Glioma, Refractory Diffuse Intrinsic Pontine Glioma, Recurrent Primary Central Nervous System Neoplasm.
What interventions are being tested in trial NCT03598244?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), X-Ray Imaging (PROCEDURE), Savolitinib (DRUG).
Who is sponsoring clinical trial NCT03598244?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03598244 being conducted?
This trial has 12 study locations across California, Colorado, District of Columbia, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
RECRUITING · Phase 1
-
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RECRUITING · Phase 1
-
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
RECRUITING · Phase 1
-
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
RECRUITING · Phase 1
-
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
ACTIVE NOT RECRUITING · Phase 1
-
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.